Table 1.

Demographic, clinical, and baseline patient characteristics

Genomic cohort (n = 12)Entire cohort (n = 24)
Age (years)
 Median62.562
 Min–max41–7841–80
Sex
 Male8 (66.7%)14 (58.3%)
 Female4 (33.3%)10 (41.6%)
Weight (kg)
 Median77.777.5
 Min–max40–10440–127.6
Ethnicity
 White or Caucasian10 (83.3%)20 (83.3%)
 African-American1 (8.3%)2 (8.3%)
 Hispanic1 (8.3%)2 (8.3%)
ECOG performance status
 04 (33.3%)10 (41.6%)
 17 (58.3%)12 (50%)
 Unknown1 (8.3%)2 (8.3%)
Smokera,b
 Yes2 (16.7%)4 (16.7%)
 No10 (83.3%)20 (83.3%)
Histology
 Adenocarcinoma11 (91.7%)23 (95.8%)
 Mixed1 (8.3%)1 (4.2%)
Stage at initial diagnosis
 III01 (4.2%)
 IIIa1 (8.3%)1 (4.2%)
 IIIb1 (8.3%)3 (12.5%)
 IV10 (83.3%)19 (79.2%)
EGFR mutation
 Negative12 (100%)24 (100%)
 Positive00
Line of treatment
 First-line9 (75%)21 (87.5%)
 Second-line3 (25%)3 (12.5%)
Number of previous anticancer therapies
 09 (75%)18 (75%)
 13 (25%)6 (25%)
Number of distant metastatic sites at study baseline
 03 (25%)4 (16.65%)
 13 (25%)10 (41.7%)
 22 (16.7%)6 (25%)
 ≥34 (33.3%)4 (16.65%)
  • aSmokers are defined as subjects that smoked at the time of enrollment or stopped within 12 months of enrollment.

  • bNonsmokers are defined as subjects that smoked ≤5 packs/year and stopped smoking at least 12 months prior to enrollment.